Sclerostin in institutionalized elderly women: Associations with quantitative bone ultrasound, bone turnover, fractures, and mortality

Journal of the American Geriatrics Society

Volumn 62, Issue 6, 2014, Pages 1023-1029

  Amrein, Karin ^a   Dobnig, Harald ^a   Wagner, Doris ^a   Piswanger Sölkner, Claudia ^a   Pieber, Thomas R ^a   Pilz, Stefan ^a   Tomaschitz, Andreas ^a   Dimai, Hans Peter ^a   Fahrleitner Pammer, Astrid ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

bone turnover; fracture risk; mortality; nursing home; sclerostin

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; GLYCOSYLATED HEMOGLOBIN; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE; SCLEROSTIN;

AGED; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE METABOLISM; BONE SONOMETER; BONE STRUCTURE; BONE TURNOVER; CALCANEUS; CALCIUM BLOOD LEVEL; COHORT ANALYSIS; CORTICAL BONE; ECHOGRAPHY; FEMALE; FOLLOW UP; FRACTURE; GLOMERULUS FILTRATION RATE; HIP FRACTURE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MINERAL METABOLISM; MORTALITY; MUSCLE STRENGTH; NURSING HOME; NURSING HOME PATIENT; OSSIFICATION; PARATHYROID HORMONE BLOOD LEVEL; PHALANX; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; QUADRICEPS FEMORIS MUSCLE; QUANTITATIVE ANALYSIS; QUANTITATIVE BONE ULTRASOUND; RADIUS; RIGIDITY; TRABECULAR BONE; ULTRASOUND BONE DENSITOMETER; VERY ELDERLY; VITAMIN BLOOD LEVEL;

BONE TURNOVER; FRACTURE RISK; MORTALITY; NURSING HOME; SCLEROSTIN;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; FEMALE; FRACTURES, BONE; GENETIC MARKERS; HUMANS; INSTITUTIONALIZATION; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84902355416     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12791     Document Type: Article

References (37)

1. Moester MJ, Papapoulos SE, Lowik CW, et al. Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int 2010; 87: 99-107.
2. Price JS, Sugiyama T, Galea GL, et al. Role of endocrine and paracrine factors in the adaptation of bone to mechanical loading. Curr Osteoporos Rep 2011; 9: 76-82.
3. Silverman SL,. Sclerostin. J Osteoporos 2010; 2010: 941419.
4. Baron R, Rawadi G,. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007; 148: 2635-2643.
5. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280: 19883-19887.
6. Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009; 24: 1651-1661.
7. Robling AG, Niziolek PJ, Baldridge LA, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008; 283: 5866-5875.
8. Claes KJ, Viaene L, Heye S, et al. Sclerostin: Another vascular calcification inhibitor? J Clin Endocrinol Metab 2013; 98: 3221-3228.
9. Moustafa A, Sugiyama T, Prasad J, et al. Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int 2012; 23: 1225-1234.
10. Gaudio A, Pennisi P, Bratengeier C, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010; 95: 2248-2253.
11. Spatz JM, Fields EE, Yu EW, et al. Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab 2012; 97: E1736-E1740.
12. Papapoulos SE,. Targeting sclerostin as potential treatment of osteoporosis. Ann Rheum Dis 2011; 70 (Suppl 1): i119-i122.
13. Becker CB,. Sclerostin inhibition for osteoporosis-A new approach. N Engl J Med 2014; 370: 476-477.
14. Cain CJ, Rueda R, McLelland B, et al. Absence of sclerostin adversely affects B-cell survival. J Bone Miner Res 2012; 27: 1451-1461.
15. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370: 412-420.
16. Garnero P, Sornay-Rendu E, Munoz F, et al. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: The OFELY Study. Osteoporos Int 2013; 24: 489-494.
17. Amrein K, Amrein S, Drexler C, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 2012; 97: 148-154.
18. Ardawi MS, Al-Kadi HA, Rouzi AA, et al. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011; 26: 2812-2822.
19. Modder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011; 26: 373-379.
20. Butler M, Norton R, Lee-Joe T, et al. The risks of hip fracture in older people from private homes and institutions. Age Ageing 1996; 25: 381-385.
21. Norton R, Campbell AJ, Reid IR, et al. Residential status and risk of hip fracture. Age Ageing 1999; 28: 135-139.
22. Ooms ME, Vlasman P, Lips P, et al. The incidence of hip fractures in independent and institutionalized elderly people. Osteoporos Int 1994; 4: 6-10.
23. Kannus P, Parkkari J, Sievanen H, et al. Epidemiology of hip fractures. Bone 1996; 18: 57S-63S.
24. Barkmann R, Gluer CC,. [Quantitative ultrasound]. Radiologe 2006; 46: 861-869.
25. Szulc P, Bertholon C, Borel O, et al. Lower fracture risk in older men with higher sclerostin concentration-A prospective analysis from the MINOS study. J Bone Miner Res 2013; 28: 855-864.
26. Arasu A, Cawthon PM, Lui LY, et al. Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab 2012; 97: 2027-2032.
27. Ardawi MS, Rouzi AA, Al-Sibiani SA, et al. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: The Center of Excellence for Osteoporosis Research Study. J Bone Miner Res 2012; 27: 2592-2602.
28. Dobnig H, Piswanger-Solkner JC, Obermayer-Pietsch B, et al. Hip and nonvertebral fracture prediction in nursing home patients: Role of bone ultrasound and bone marker measurements. J Clin Endocrinol Metab 2007; 92: 1678-1686.
29. Dobnig H, Piswanger-Solkner JC, Roth M, et al. Type 2 diabetes mellitus in nursing home patients: Effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 2006; 91: 3355-3363.
30. Herrmann W, Kirsch SH, Kruse V, et al. One year B and D vitamins supplementation improves metabolic bone markers. Clin Chem Lab Med 2013; 51: 639-647.
31. Rack B, Lochmuller EM, Janni W, et al. Ultrasound for the assessment of bone quality in preterm and term infants. J Perinatol 2012; 32: 218-226.
32. Babatunde OO, Forsyth JJ,. Quantitative ultrasound and bone's response to exercise: A meta analysis. Bone 2013; 53: 311-318.
33. Ardawi MS, Rouzi AA, Qari MH,. Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: A cross-sectional and a longitudinal study. J Clin Endocrinol Metab 2012; 97: 3691-3699.
34. Jastrzebski S, Kalinowski J, Stolina M, et al. Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. J Bone Miner Res 2013; 28: 618-626.
35. Drake MT, Srinivasan B, Modder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010; 95: 5056-5062.
36. Ivaska KK, Gerdhem P, Vaananen HK, et al. Bone turnover markers and prediction of fracture: A prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res 2010; 25: 393-403.
37. Lee J, Vasikaran S,. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med 2012; 32: 105-112.